Salminen M K, Rautelin H, Tynkkynen S, Poussa T, Saxelin M, Valtonen V, Järvinen A
Division of Infectious Diseases, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland.
Clin Infect Dis. 2006 Mar 1;42(5):e35-44. doi: 10.1086/500214. Epub 2006 Jan 25.
Data regarding antimicrobial susceptibility of clinical Lactobacillus isolates are scarce, and appropriate interpretation criteria for susceptibility tests are not available.
We examined 85 cases of Lactobacillus bacteremia, of which 47 cases have been included in our previous studies. Overall, 14 antimicrobial agents were evaluated by the E-test method, and these results were compared with disk diffusion test findings. The clinical outcomes of the patients and their antimicrobial treatments were registered.
The antimicrobial susceptibility of Lactobacillus strains was species dependent. The considerable number of Lactobacillus rhamnosus (n=46), Lactobacillus fermentum (n=12), and Lactobacillus casei (n=12) strains available for testing made it possible to compare the susceptibilities within 1 species, as well. Of the 46 L. rhamnosus isolates, 22 were identified as L. rhamnosus GG type by pulsed-field gel electrophoresis. All Lactobacillus isolates demonstrated low minimum inhibitory concentrations (MICs) of imipenem, piperacillin-tazobactam, erythromycin, and clindamycin. MICs of vancomycin were high (>256 microg/mL) for all other species except Lactobacillus gasseri and Lactobacillus jensenii. Disk diffusion and E-test results were concordant. The MICs of cephalosporins varied; cefuroxime demonstrated a higher level of activity than did ceftriaxone. Benzylpenicillin and ampicillin MICs had variable ranges between different species. Combination therapy was given to 83% of the patients, but, in 54% of them, therapy included only 1 microbiologically active agent, according to results of the susceptibility tests. Mortality at 1 week was 12% among patients who presumably were receiving adequate treatment and 27% among patients who were receiving inadequate treatment (P=.131, by E-test).
Most clinical Lactobacillus blood isolates demonstrated low MICs of imipenem, piperacillin-tazobactam, erythromycin, and clindamycin, but they had variable susceptibility to penicillin and cephalosporins.
关于临床分离的乳酸杆菌对抗菌药物敏感性的数据稀缺,且尚无药敏试验的合适解读标准。
我们检查了85例乳酸杆菌血症病例,其中47例已纳入我们之前的研究。总体而言,采用E试验法评估了14种抗菌药物,并将这些结果与纸片扩散法试验结果进行比较。记录患者的临床结局及其抗菌治疗情况。
乳酸杆菌菌株的抗菌药物敏感性因菌种而异。有相当数量的鼠李糖乳杆菌(n = 46)、发酵乳杆菌(n = 12)和干酪乳杆菌(n = 12)菌株可供测试,这使得也能够比较同一菌种内的敏感性。在46株鼠李糖乳杆菌分离株中,通过脉冲场凝胶电泳鉴定出22株为鼠李糖乳杆菌GG型。所有乳酸杆菌分离株对亚胺培南、哌拉西林 - 他唑巴坦、红霉素和克林霉素均显示出低最低抑菌浓度(MIC)。除加氏乳杆菌和詹氏乳杆菌外,所有其他菌种的万古霉素MIC均较高(>256μg/mL)。纸片扩散法和E试验结果一致。头孢菌素的MIC各不相同;头孢呋辛显示出比头孢曲松更高的活性水平。苄青霉素和氨苄青霉素的MIC在不同菌种之间有不同范围。83%的患者接受了联合治疗,但根据药敏试验结果,其中54%的患者治疗仅包括1种有微生物活性的药物。在推测接受了充分治疗的患者中,1周时的死亡率为12%,在接受不充分治疗的患者中为27%(通过E试验,P = 0.131)。
大多数临床分离的乳酸杆菌血培养株对亚胺培南、哌拉西林 - 他唑巴坦、红霉素和克林霉素显示出低MIC,但它们对青霉素和头孢菌素的敏感性各不相同。